Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

…, T Coetzee, G Comi, J Correale, F Fazekas… - The Lancet …, 2018 - thelancet.com
The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in
research and clinical practice. Scientific advances in the past 7 years suggest that they might …

Neurofilaments as biomarkers in neurological disorders

…, C Barro, L Kappos, M Comabella, F Fazekas… - Nature Reviews …, 2018 - nature.com
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …

2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis

…, N de Stefano, C Enzinger, F Fazekas… - The Lancet …, 2021 - thelancet.com
Summary The 2015 Magnetic Resonance Imaging in Multiple Sclerosis and 2016
Consortium of Multiple Sclerosis Centres guidelines on the use of MRI in diagnosis and …

Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration

…, GJ Biessels, C Cordonnier, F Fazekas… - The Lancet …, 2013 - thelancet.com
Cerebral small vessel disease (SVD) is a common accompaniment of ageing. Features seen
on neuroimaging include recent small subcortical infarcts, lacunes, white matter …

A new rating scale for age-related white matter changes applicable to MRI and CT

LO Wahlund, F Barkhof, F Fazekas, L Bronge… - Stroke, 2001 - Am Heart Assoc
Background and Purpose—MRI is more sensitive than CT for detection of age-related white
matter changes (ARWMC). Most rating scales estimate the degree and distribution of …

Pathologic correlates of incidental MRI white matter signal hyperintensities

F Fazekas, R Kleinert, H Offenbacher, R Schmidt… - Neurology, 1993 - AAN Enterprises
We related the histopathologic changes associated with incidental white matter signal
hyperintensities on MRIs from 11 elderly patients (age range, 52 to 82 years) to a descriptive …

MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging

F Fazekas, JB Chawluk, A Alavi… - American journal of …, 1987 - Am Roentgen Ray Soc
The type, frequency, and extent of MR signal abnormalities in Alzheimer's disease and
normal aging are a subject of controversy. With a 1.5-MR unit we studied 12 Alzheimer …

[HTML][HTML] MRI-guided thrombolysis for stroke with unknown time of onset

…, B Cheripelli, TH Cho, F Fazekas… - … England Journal of …, 2018 - Mass Medical Soc
Background Under current guidelines, intravenous thrombolysis is used to treat acute stroke
only if it can be ascertained that the time since the onset of symptoms was less than 4.5 …

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double …

…, L Moiola, O Bajenaru, A Carra, I Elovaara, F Fazekas… - The Lancet, 2009 - thelancet.com
Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple
sclerosis, reduces relapses and disease activity and burden monitored by MRI. We …

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis

…, G Comi, T Derfuss, F Fazekas… - Multiple Sclerosis …, 2018 - journals.sagepub.com
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …